(Q38184585)

30 August 2017

title

Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development? (English)

1 reference

30 August 2017

0 references

Laura Runkel

1

1 reference

30 August 2017

Jennifer Stacey

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

3 February 2014

1 reference

Expert Opinion on Biological Therapy

30 August 2017

published in

1 reference

30 August 2017

volume

14

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

491-501

1 reference

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Novel evidence-based systemic lupus erythematosus responder index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

The discovery and development of belimumab: the anti-BLyS-lupus connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Biologics in SLE: towards new approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Type I interferon in organ-targeted autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

Nucleic Acid sensors and type I interferon production in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.884065

10.1517/14712598.2014.884065

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference